INVENTIVA: directors' dealings · France · AMF

About INVENTIVA

Inventiva is a French clinical-stage biopharmaceutical company listed under ISIN FR0013233012 and headquartered in Daix, Burgundy, France. Founded in 2011 by former executives of the French subsidiary of Solvay, the company began operating in 2012 after acquiring an integrated R&D platform. Its scientific roots are closely linked to legacy assets and expertise inherited from Abbott, Solvay and Fournier, which helped establish an internal research base focused on small-molecule drug discovery. Over time, Inventiva positioned itself as a specialist in orally administered therapies for diseases with high unmet medical need, initially spanning fibrosis, lysosomal storage disorders and oncology. Inventiva’s current strategy is highly concentrated on lanifibranor, its lead product candidate, which is being evaluated in the pivotal Phase 3 NATiV3 trial for the treatment of MASH (metabolic dysfunction-associated steatohepatitis) with advanced fibrosis. MASH is a progressive liver disease associated with metabolic dysfunction and can lead to cirrhosis and liver-related complications. Lanifibranor is designed as a pan-PPAR modulator targeting key disease pathways: steatosis, inflammation and fibrosis. The company reported positive Phase 2b data showing statistically significant efficacy on key regulatory endpoints, together with a favorable safety profile, which supported FDA Breakthrough Therapy Designation. These data underpin Inventiva’s ambition to deliver a differentiated oral therapeutic option in a large and still underserved market. Historically, Inventiva pursued a broader pipeline, including programs in rare diseases such as mucopolysaccharidoses, as well as earlier-stage oncology and fibrosis assets. However, the company has recently sharpened its strategic focus and streamlined resources toward lanifibranor to maximize the probability of success and preserve capital. This refocusing came alongside operational reorganization and financing actions, reflecting the capital-intensive nature of late-stage biotech development. Geographically, Inventiva is a French company with international reach. Its clinical programs have been developed through a broad network of trial sites, including the United States, Europe and selected Asian markets, and the company has maintained visibility in both Euronext and U.S. investor circles. Notable facts include its transition from a diversified pipeline to a single-asset focus, its advanced clinical status, and the fact that it remains one of the more closely watched French biotech names in the metabolic-liver disease space. Inventiva’s investment case is therefore closely tied to clinical execution, regulatory milestones and the eventual commercial potential of lanifibranor.